Treatments of activated ILC2s with DTA-1, a monoclonal agonistic antibody targeting GITR, were able to prevent metabolic disturbances induced by HFD, improve glucose homeostasis, and reverse established insulin resistance in mouse models (20). This evidence concerns the gene TNFRSF18 and Insulin resistance.